RxDoctor Payments Data

Melanie Bennett Sims, MD

Ophthalmology · Baltimore, MDNPI 1982896106

Payments from drug & device makers

$1,489in general payments, 2019–2025

Across 61 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Oyster Point Pharma, Inc.$395
  • Bausch & Lomb Americas Inc.$184
  • Sun Pharmaceutical Industries Inc.$159
  • Harrow Eye, LLC$114
  • Tarsus Pharmaceuticals, Inc.$96
  • AbbVie$93
  • plus $447 from 10 others

What the payments were for

  • Food & beverage$1,489100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,489 in reported general payments places this provider in the 50th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$87,076
Medicare patients
326
Services billed
1,098

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine94$140,243
XiidraLifitegrast59$82,791
MieboPerfluorohexyloctane/Pf36$43,952
CequaCyclosporine30$32,664
LumiganBimatoprost53$32,559
TyrvayaVarenicline Tartrate18$30,822
Cyclosporine51$15,859
VyzultaLatanoprostene Bunod23$13,311
CombiganBrimonidine Tartrate/Timolol24$8,507
SimbrinzaBrinzolamide/Brimonidine Tart30$8,131
Alphagan PBrimonidine Tartrate12$6,143
Travoprost41$5,221
Tobramycin-DexamethasoneTobramycin/Dexamethasone106$4,293
TobradexTobramycin/Dexamethasone15$3,959
Latanoprost233$2,917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$93$187,452183 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$184$140,054118 claims
Sun Pharmaceutical Industries Inc.Cequa$159$32,66430 claims
Oyster Point Pharma, Inc.Tyrvaya$395$30,82218 claims
AlconSimbrinza$37$8,13130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →